Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive crawled date : 2021 - 06 - 28 save search
Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis
Published: 2021-06-28 (Crawled : 20:00) - globenewswire.com
ENTX | $2.22 8.29% 7.66% 110K
|
Health Technology
|
| O: -0.66%
H: 0.36%
C: -4.15%
AMGN | News | $273.69 0.66% 0.65% 2.5M
|
Health Technology
|
| O: 0.16%
H: 0.3%
C: -0.31%
treatment phase 2 bone phase 2 results results eb613 conference osteoporosis
Medtronic InPen™ Real-World Data and Extended Infusion Set* Pivotal Trial Results Demonstrate Strong Clinical Outcomes and Positive User Experience
Published: 2021-06-28 (Crawled : 17:00) - biospace.com/
MDT | $81.29 0.89% 0.0% 5.2M
|
Health Technology
|
| O: 0.29%
H: 0.1%
C: -1.24%
positive trial trial results
Eiger BioPharmaceuticals Announces Presentation of Positive Phase 2 Results of Avexitide in Congenital Hyperinsulinism at the American Diabetes Association Virtual 81st Scientific Session
Published: 2021-06-28 (Crawled : 16:00) - biospace.com/
EIGR | $1.725 -1.45% 140K
|
Health Technology
|
| O: 4.84%
H: 5.28%
C: -1.65%
presentation diabetes phase 2 biopharma positive phase 2 results results insulin
MYM’s Acquisition by IMCC Receives Positive Recommendations from leading Independent Proxy Advisory Firms
Published: 2021-06-28 (Crawled : 14:00) - globenewswire.com
IMCC | $0.611 -15.93% -18.95% 600K
|
Manufacturing
|
| O: 2.56%
H: 3.27%
C: 3.27%
acquisition positive
Daré Bioscience Announces Positive Phase 1 Results for DARE-HRT1
Published: 2021-06-28 (Crawled : 12:15) - globenewswire.com
DARE | $0.306 3.62% 3.5% 320K
|
Health Technology
|
| O: 0.0%
H: 1.78%
C: -0.59%
phase 1 positive results phase 2 phase 3 bioscience
Hoth Therapeutics Announces Positive Safety Results from AD001 Cohort 1 of Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis
Published: 2021-06-28 (Crawled : 12:00) - ir.hoththerapeutics.com
HOTH | $1.15 1.2% 29K
|
Health Technology
|
| O: 1.26%
H: 4.97%
C: -1.86%
treatment phase 1 positive results dermatitis trial atopic dermatitis phase 1b al001 adi-001 phase 2b
Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism
Published: 2021-06-28 (Crawled : 10:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.34%
H: 0.47%
C: 0.24%
KYMR | $35.7 3.93% 3.78% 440K
|
Health Technology
|
| O: 2.97%
H: 3.46%
C: 3.24%
phase 1 positive results trial phase 2
Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial
Published: 2021-06-28 (Crawled : 08:00) - biospace.com/
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.34%
H: 0.47%
C: 0.24%
phase 2 phase 2/3 positive results topline trial
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.